Bacterial Vaginosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 73 Published: March 31, 2022 Report Code: GMDGDHC22047IDB

Bacterial vaginosis (BV), also known as vaginal bacteriosis is a type of vaginal inflammation caused by overgrowth of bacteria  present  in  vagina.  Symptoms  include  vaginal  itching;  burning  during  urination  and  vaginal  discharge  may become watery and thin. Treatment includes antibiotics.

The Bacterial Vaginosis -Drugs In Development research report provides a comprehensive overview on the therapeutics under development for  Bacterial  Vaginosis,  complete  with  analysis  by  stage  of  development,  drug  target,  mechanism  of  action  (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics,  its  complete  research  and  development  history  and  latest  news  and  press  releases.  Additionally,  the report provides an overview of key players involved in therapeutic development for Bacterial Vaginosis and features dormant and discontinued projects.

Key Targets in the Bacterial Vaginosis pipeline drugs market

The key targets in the Bacterial Vaginosis pipeline drugs market are 23S Ribosomal RNA, Bacterial Cell Wall, DNA, Lanosterol 14 Alpha Demethylase, Prostaglandin G/H Synthase 1, and Prostaglandin G/H Synthase 2.

Bacterial Vaginosis Pipeline Drugs Market, by Targets

Bacterial Vaginosis Pipeline Drugs Market, by Targets

For more target insights, download a free report sample

Key MoA in the Bacterial Vaginosis Pipeline Drugs Market

The key mechanisms of action in the Bacterial Vaginosis pipeline drugs market are 23S Ribosomal RNA inhibitor, Bacterial Cell Wall inhibitor, DNA inhibitor, Lanosterol 14 Alpha Demethylase inhibitor, Prostaglandin G/H Synthase 1 inhibitor, and Prostaglandin G/H Synthase 2 inhibitor.

Bacterial Vaginosis Pipeline Drugs Market, by MoA

Bacterial Vaginosis Pipeline Drugs Market, by MoA

To get more insights on key MoA, download a free report sample

Key Molecule Types in the Bacterial Vaginosis Pipeline Drugs Market

The key molecule types in the Bacterial Vaginosis pipeline drugs market are small molecule, biologic, peptide, and recombinant enzyme.

Bacterial Vaginosis Pipeline Drugs Market, by Molecule Types

Bacterial Vaginosis Pipeline Drugs Market, by Molecule Types

To get more insights on key molecule types, download a free report sample

Key RoA in the Bacterial Vaginosis Pipeline Drugs Market

The key routes of administration in the Bacterial Vaginosis pipeline drugs market are intravenous, vaginal, oral, topical, nasal and ophthalmic.

Bacterial Vaginosis Pipeline Drugs Market, by RoA

Bacterial Vaginosis Pipeline Drugs Market, by RoA

To get more insights on key RoA, download a free report sample

Major Companies in the Bacterial Vaginosis Pipeline Drugs Market

The major companies in the Bacterial Vaginosis pipeline drugs market are Starpharma Holdings Ltd, AtoGen Co Ltd, BioNTech SE, Evofem Biosciences Inc, Ferring Pharmaceuticals Inc, and Melinta Therapeutics Inc among others.

Bacterial Vaginosis Pipeline Drugs Market, by Companies

Bacterial Vaginosis Pipeline Drugs Market, by Companies

For more company insights, download a free report sample

Bacterial Vaginosis Pipeline Drugs Market Overview

Key target 23S Ribosomal RNA, Bacterial Cell Wall, DNA, Lanosterol 14 Alpha Demethylase, Prostaglandin G/H Synthase 1, and Prostaglandin G/H Synthase 2.

 

key mechanism of action 23S Ribosomal RNA inhibitor, Bacterial Cell Wall inhibitor, DNA inhibitor, Lanosterol 14 Alpha Demethylase Inhibitor, Prostaglandin G/H Synthase 1 Inhibitor, And Prostaglandin G/H Synthase 2 Inhibitor
Key molecule types Small Molecule, Biologic, Peptide, and Recombinant Enzyme

 

Key routes of administration Intravenous, Vaginal, Oral, Topical, Nasal and Ophthalmic

 

Major companies Starpharma Holdings Ltd, AtoGen Co Ltd, BioNTech SE, Evofem Biosciences Inc, Ferring Pharmaceuticals Inc, and Melinta Therapeutics Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bacterial Vaginosis
  • The pipeline guide reviews pipeline therapeutics for Bacterial Vaginosis by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bacterial Vaginosis therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bacterial Vaginosis therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Bacterial Vaginosis

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bacterial Vaginosis
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bacterial Vaginosis pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Key Players

AtoGen Co Ltd

BioNTech SE

Evofem Biosciences Inc

Ferring Pharmaceuticals Inc

Guangdong Longchuangji Pharmaceutical Co Ltd

Hammock Pharmaceuticals Inc

Hennepin Life Sciences LLC

Melinta Therapeutics Inc

Mucommune LLC

MyBiotics Pharma Ltd

Next Science Ltd

Osel Inc

Pharmiva AB

Profem GmbH

Seed Health Inc

Sichuan Anaerobic Biotechnology Co Ltd

Starpharma Holdings Ltd

Suzhou Kanger Biomedical Co Ltd

Suzhou Ousai Weike Biomedical Technology Co Ltd

TenNor Therapeutics Ltd

Toltec Pharmaceuticals LLC

Zhejiang Xinlifei Biotechnology Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Bacterial Vaginosis – Overview

Bacterial Vaginosis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Bacterial Vaginosis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bacterial Vaginosis – Companies Involved in Therapeutics Development

AtoGen Co Ltd

BioNTech SE

Evofem Biosciences Inc

Ferring Pharmaceuticals Inc

Guangdong Longchuangji Pharmaceutical Co Ltd

Hammock Pharmaceuticals Inc

Hennepin Life Sciences LLC

Melinta Therapeutics Inc

Mucommune LLC

MyBiotics Pharma Ltd

Next Science Ltd

Osel Inc

Pharmiva AB

Profem GmbH

Seed Health Inc

Sichuan Anaerobic Biotechnology Co Ltd

Starpharma Holdings Ltd

Suzhou Kanger Biomedical Co Ltd

Suzhou Ousai Weike Biomedical Technology Co Ltd

TenNor Therapeutics Ltd

Toltec Pharmaceuticals LLC

Zhejiang Xinlifei Biotechnology Co Ltd

Bacterial Vaginosis – Drug Profiles

(citric acid + lactic acid + potassium bitartrate) – Drug Profile

Product Description

Mechanism Of Action

History of Events

astodrimer – Drug Profile

Product Description

Mechanism Of Action

History of Events

Biologic for Bacterial Vaginosis – Drug Profile

Product Description

Mechanism Of Action

Biologic for Bacterial Vaginosis – Drug Profile

Product Description

Mechanism Of Action

Biologics for Bacterial Vaginosis – Drug Profile

Product Description

Mechanism Of Action

History of Events

Drug for Bacterial Vaginosis – Drug Profile

Product Description

Mechanism Of Action

Golden Ring Snake Antibacterial Peptide – Drug Profile

Product Description

Mechanism Of Action

KAL-001 – Drug Profile

Product Description

Mechanism Of Action

LABthera-001 – Drug Profile

Product Description

Mechanism Of Action

lactic acid SR – Drug Profile

Product Description

Mechanism Of Action

History of Events

LACTIN-V – Drug Profile

Product Description

Mechanism Of Action

History of Events

Lactobacillus dual live bacteria – Drug Profile

Product Description

Mechanism Of Action

MBXSD-103 – Drug Profile

Product Description

Mechanism Of Action

metronidazole – Drug Profile

Product Description

Mechanism Of Action

History of Events

P-001 – Drug Profile

Product Description

Mechanism Of Action

PM-477 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Prof-002 – Drug Profile

Product Description

Mechanism Of Action

radezolid – Drug Profile

Product Description

Mechanism Of Action

Small Molecule for Bacterial Vaginosis and Candidiasis – Drug Profile

Product Description

Mechanism Of Action

subtilosin – Drug Profile

Product Description

Mechanism Of Action

TNP-2198 – Drug Profile

Product Description

Mechanism Of Action

History of Events

TOL-463 – Drug Profile

Product Description

Mechanism Of Action

History of Events

VMSC-015 – Drug Profile

Product Description

Mechanism Of Action

Bacterial Vaginosis – Dormant Projects

Bacterial Vaginosis – Discontinued Products

Bacterial Vaginosis – Product Development Milestones

Featured News & Press Releases

Sep 25, 2020: VivaGel BV secures TGA approval for prevention of BV

Jun 16, 2020: VivaGel BV launched in central and eastern European countries

May 13, 2020: Osel’s live biotherapeutic product demonstrates efficacy in phase 2b study of bacterial vaginosis

Nov 13, 2019: Starpharma announces UK launch of VivaGel BV

Sep 28, 2019: Congratulations to Guangdong Longchuangji Pharmaceutical a subsidiary of Qiangji Pharmaceutical, for obtaining clinical approval for the “Vaginal Lactobacillus Double Live Capsules” developed

Sep 03, 2019: VivaGel BV regulatory approvals continue in Asia

Aug 15, 2019: First Asian regulatory approvals received for VivaGel BV

Apr 16, 2019: First VivaGel BV launch globally in Australia by Aspen

Sep 21, 2018: New Data on Patient Acceptability and Genitourinary Effects of Evofem Biosciences’ Amphora and its Role as a Multipurpose Vaginal pH Regulator (MVP-R) to be Presented at the 2018 American Society For Reproductive Medicine Annual Congress

Jul 09, 2018: VivaGel BV NDA advances to next stage of FDA review

Apr 30, 2018: Starpharma completes US New Drug Application for VivaGel BV

Jan 18, 2018: Melinta Therapeutics Announces Initiation of Program for Radezolid in Patients with Bacterial Vaginosis

Jan 17, 2018: Osel’s LACTIN-V Enters Clinical Study to Improve the Success Rate of IVF in Women With Imbalanced Vaginal Microbiomes

Nov 21, 2017: Starpharma: NDA submission for VivaGel BV in the US

Oct 25, 2017: VivaGel BV granted marketing approval in Australia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Bacterial Vaginosis, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Bacterial Vaginosis – Pipeline by AtoGen Co Ltd, 2022

Bacterial Vaginosis – Pipeline by BioNTech SE, 2022

Bacterial Vaginosis – Pipeline by Evofem Biosciences Inc, 2022

Bacterial Vaginosis – Pipeline by Ferring Pharmaceuticals Inc, 2022

Bacterial Vaginosis – Pipeline by Guangdong Longchuangji Pharmaceutical Co Ltd, 2022

Bacterial Vaginosis – Pipeline by Hammock Pharmaceuticals Inc, 2022

Bacterial Vaginosis – Pipeline by Hennepin Life Sciences LLC, 2022

Bacterial Vaginosis – Pipeline by Melinta Therapeutics Inc, 2022

Bacterial Vaginosis – Pipeline by Mucommune LLC, 2022

Bacterial Vaginosis – Pipeline by MyBiotics Pharma Ltd, 2022

Bacterial Vaginosis – Pipeline by Next Science Ltd, 2022

Bacterial Vaginosis – Pipeline by Osel Inc, 2022

Bacterial Vaginosis – Pipeline by Pharmiva AB, 2022

Bacterial Vaginosis – Pipeline by Profem GmbH, 2022

Bacterial Vaginosis – Pipeline by Seed Health Inc, 2022

Bacterial Vaginosis – Pipeline by Sichuan Anaerobic Biotechnology Co Ltd, 2022

Bacterial Vaginosis – Pipeline by Starpharma Holdings Ltd, 2022

Bacterial Vaginosis – Pipeline by Suzhou Kanger Biomedical Co Ltd, 2022

Bacterial Vaginosis – Pipeline by Suzhou Ousai Weike Biomedical Technology Co Ltd, 2022

Bacterial Vaginosis – Pipeline by TenNor Therapeutics Ltd, 2022

Bacterial Vaginosis – Pipeline by Toltec Pharmaceuticals LLC, 2022

Bacterial Vaginosis – Pipeline by Zhejiang Xinlifei Biotechnology Co Ltd, 2022

Bacterial Vaginosis – Dormant Projects, 2022

Bacterial Vaginosis – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Bacterial Vaginosis, 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently Asked Questions

Enquire Before Buying
$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.